Cell and gene therapies are overlapping fields of research and treatments. While both aim to treat and potentially cure diseases, they have slightly differing approaches and have different historical backgrounds. Due to growing interest surrounding this field, the general public still has much to learn and understand about each of these potentially life-saving therapies.
Below, we provide a general overview and brief historical context for each type of therapy.
Cell therapyis the process of replacing damaged or dysfunctional cells with new, healthy ones by transferring live cells into a patient. These can be autologous (also known as self-to-self, using cells from the patient receiving the treatment) or allogeneic (using cells from a donor for the treatment). While this field of treatment has recently begun to expand, some forms of cell therapy like the cancer-treating hematopoietic stem cell transplantation(HSCT) have been in practice for decades.
While many people have heard of bone marrow transplants, few realize that this procedure is a stem cell therapy. While stem cells can be derived from many sources, such as umbilical cord blood and mobilized peripheral blood, bone marrow derived stem cell therapy is the most commonly used today and has been for more than 50 years.
The first transfusion of human bone marrow was given to a patient with aplastic anemia in 1939. After World War II researchers diligently worked to restore bone marrow function in aplasia patients caused by exposure to radiation produced by the atomic bomb. After a decade of work they were able to show, in a mouse model, that aplasia could be overcome by bone marrow treatment.
The first allogeneic HSCT, which led the way to current protocols, was pioneered by E. Donnall Thomas and his team at the Fred Hutchinson Cancer Research Center and reported in the New England Journal of Medicine in 1957. In this study six patients were treated with radiation and chemotherapy and then received intravenous infusion of bone marrow rich stem cells from a normal donor to reestablish the damaged or defective cells. Since then the field has evolved and expanded worldwide. While almost half of HSCT are allogeneic, the majority of HSCT are autologous, the patient's own stem cells are used for treatment, which carries less risk to the patient.
In 1988, scientists discovered that they could derive stem cells from human embryos and grow the cells in a laboratory. These newly derived stem cells, referred to as embryonic stem cells (hESCs), were found to be pluripotent, meaning they can give rise to virtually any other type of cell in the body. This versatility allows hESCs cells to potentially regenerate or repair diseased tissue and organs. Two decades after they were discovered, treatments based on hESCs have been slow in coming because of controversy over their source and concerns that they could turn into tumours once implanted. Only recently, testing has begun as a treatment for two major diseases: heart failure and type 1 diabetes.
In 2006, researchers made a groundbreaking discovery by identifying conditions that would allow some cells to be 'reprogrammed' genetically. This new type of stem cell became known as induced pluripotent stem cells (iPSCs). Since this discovery, the field has expanded tremendously in the past two decades. Stem cell therapies have expanded in use and have been used to treat diseases such as type 1 diabetes, Parkinson's and even spinal cord injuries.
There has also been a growing focus on using other immune cells to treat cancer. Therapies such as CAR T-cellare dependent upon a patient's T-cells, which play a critical role in managing the immune response and killing cells affected by harmful pathogens. These cells are then reengineered to target and kill certain cancerous cells. Several CAR T-cell therapies have been FDA approved, with the first approval being given in 2017 for Yescarta and Kymriah, to be used for the treatment of B-cell leukemia in children and young adults.
Gene therapyis a process that modifies the expression of a gene or alters the biological process of living cells for therapeutic use. This process can take the form of replacing a disease-causing gene with a new, healthy one, inactivating the mutated gene, or introducing a new gene to help the patient's body fight a disease.
While the use of gene therapy to treat humans is fairly new, the science behind it has been used in science for decades. Farmers and geneticists have collaborated for years on crop improvement using cross pollination, genetic engineering and microinjection techniques to create stronger, more resilient crops.
The first human patient to be treated with gene therapy was a four-year old girlsuffering from severe combined immunodeficiencyin 1990. She received treatment for a congenital disease called adenosine deaminase (ADA). Since then, gene therapies have been used to treat diseases such as cancer, cystic fibrosis and hemophilia.In 2017, the FDA gave its first approval of a gene therapy called Luxturna, which is used to treat patients with established genetic vision loss that may result in blindness. Gene therapies are still being studied and developed, with over 1,000 clinical trialscurrently underway.
ThermoGenesis Holdings Inc., is a pioneer and market leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We market a full suite of solutions for automated clinical biobanking, point-of-care applications and large-scale cell processing and manufacturing with a special emphasis on the emerging CAR-T immunotherapy market. We are committed to making the world a healthier place by creating innovative solutions for those in need.
For more information on the CAR-TXpress multi-system platform, please contact our Sales team.
Disclaimer
Thermogenesis Holdings Inc. published this content on 13 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2021 07:10:03 UTC.
Originally posted here:
ThermoGenesis : The History of Cell and Gene Therapy - Marketscreener.com
- Umbilical Cord Blood Banking Market Size Set to Reach $7.9 Billion by 2031 Driven by Growing Awareness and Hybrid Models - Exclusive Report by The... - February 11th, 2025
- Immune Complex Shaves Stem Cells to Protect against Cancer - February 4th, 2025
- Should I bank my newborn's umbilical cord blood? | BabyCentre - February 4th, 2025
- Characteristics of Parthenogenetic Stem Cells and Their Potential ... - February 4th, 2025
- Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives - Business Wire - January 31st, 2025
- Edmontons Lois Hole Hospital collects 9,000 units of cord blood since launching 10 years ago - CityNews Edmonton - January 21st, 2025
- Lois Hole Hospital for Women celebrates 10 years as cord blood collection site - CTV News - January 21st, 2025
- LMRUK: 10 years of fighting blood cancer - Charity Today News - January 21st, 2025
- A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia -... - December 22nd, 2024
- Hope for the treatment of alzheimers disease may lie in umbilical cord stem cells - The Portugal News - December 20th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Cord Blood & Uses to Treat Disease About Stem Cells - December 17th, 2024
- LMRUK: New mothers share why theyre banking their babies cord blood stem cells - Charity Today News - November 29th, 2024
- scRNA-seq revealed transcriptional signatures of human umbilical cord primitive stem cells and their germ lineage origin regulated by imprinted genes... - November 26th, 2024
- Cord Blood Banking FAQs - Cord For Life - November 25th, 2024
- Hematopoietic Stem Cell Transplantation Market: Industry Analysis and Forecast 2024-2033 - openPR - November 22nd, 2024
- Thousands of donations, fewer than 2% used. Why cord blood transplants are so rare - CBC News - November 18th, 2024
- Stem cells: the alternative solution to umbilical cord blood - Genethique - November 10th, 2024
- Chapter 64 Role of Umbilical Cord Blood Transplantation - October 30th, 2024
- Major Trend Transforming the Stem Cell Market in 2024: Advancements in Automated Stem Cell Analysis Systems - EIN News - October 30th, 2024
- Stem cell therapies for neurological disorders: current progress ... - October 22nd, 2024
- OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients - AsiaOne - October 18th, 2024
- Click N' Play STEM Lesson on Cord Blood Launches for Teachers this November - EIN News - October 18th, 2024
- Black, White Cancer Patients Now Benefit Equally From Cord Blood Therapy - HealthDay - October 4th, 2024
- What Are Leukemia and Lymphoma and How Are They Treated? - LVHN News - September 20th, 2024
- Advanced Treatment for Leukemia and Lymphoma at Lehigh Valley Topper Cancer Institute - LVHN News - September 18th, 2024
- Functional stem cells successfully grown in lab for the first time - The Star Online - September 14th, 2024
- Umbilical Cord Blood Stem Cells as Third-party Adjuvant Infusions in Human Leukocyte Antigen Antibody-Positive Patients Undergoing Haploidentical... - September 12th, 2024
- Cord Blood Banking Market Size to Surpass USD 65.6 Billion by 2032 | With 7.9% CAGR - openPR - September 12th, 2024
- Blood stem cell breakthrough could have massive impact on patients - Yahoo! Voices - September 8th, 2024
- Scientists have grown blood stem cells in the laboratory - TURKMENPORTAL - September 4th, 2024
- Global Cord Blood Product Market Poised for Significant Growth: Projected to Reach USD 1,341.7 Million by 2034 | Future Market Insights, Inc. - Yahoo... - September 2nd, 2024
- Global Allogeneic Stem Cell Transplantation Market Expected to Grow to $6.75 Billion by 2031 - WhaTech - August 31st, 2024
- Global Cord Blood Product Market Poised for Significant Growth: Projected to Reach USD 1,341.7 Million by 2034 | Future Market Insights, Inc. -... - August 31st, 2024
- Expansion Of Cord Blood-derived CD34 Cells In A Hollow-Fiber Bioreactor With 10% Standard Cytokine Concentration - BioProcess Online - August 22nd, 2024
- New Study: These Bizarre Blood-Sucking Fish Have a Jaw-Dropping Evolutionary Origin - SciTechDaily - July 31st, 2024
- Cord blood banking industry faces scrutiny over unproven claims and high costs - News-Medical.Net - July 28th, 2024
- Stem cells donated 15 years ago let poorly boy, five, leave home for the first time in six months - Express & Star - July 26th, 2024
- Cord blood stem cells transferred from Guangdong to treat girl with thalassemia - Hong Kong Standard - July 26th, 2024
- Cord Blood Banking Curative Benefits Often Oversold to Parents: NYT Investigation - AboutLawsuits.com - July 22nd, 2024
- Umbilical cord stem cells donated in 2008 transform life of five-year-old boy with rare genetic disorder - The Independent - July 22nd, 2024
- Boy, 5, diagnosed with deadly rare condition has life transformed after stem cell transplant from umbilical cord blood - Sky News - July 22nd, 2024
- Stem cells donated 15 years ago let poorly boy, five, leave home for the first time in six months - Shropshire Star - July 22nd, 2024
- Ottawa mother raising awareness on importance of donating umbilical cord blood - CTV News Ottawa - July 22nd, 2024
- Inside a blood cord bank: How facilities store and maintain the quality of units - CNA - July 8th, 2024
- Exploring the potential of predicted miRNAs on the genes involved in the expansion of hematopoietic stem cells ... - Nature.com - July 5th, 2024
- Overview of Umbilical Cord Blood - Stanford Medicine - July 5th, 2024
- Comparison of the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells and adipose ... - Frontiers - July 5th, 2024
- A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic ... - Frontiers - July 2nd, 2024
- Jacques Galipeau, MD, on International Insights Into Cell and Gene Therapy Development - CGTLive - June 30th, 2024
- Stem Cell Therapy Market to Hit $63.23 billion by 2031, at a CAGR of 22.6%, says Coherent Market Insights - GlobeNewswire - June 28th, 2024
- Hematopoietic stem cell transplantation (HSCT) Market Future Growth Trends, Upcoming Opportunities and ... - openPR - June 24th, 2024
- Global Biopreservation Market Forecast Report 2024-2029: Advances in Biobanking and Growing Trend of Conserving ... - GlobeNewswire - June 4th, 2024
- Cord Blood Banking Services Market to Witness Impressive Growth, Reaching USD 4.5 Billion by 2030 - EIN News - May 27th, 2024
- Department of Health Abu Dhabi and M42 launch regions largest hybrid cord blood bank - ZAWYA - May 15th, 2024
- Cord Blood Banking - Stanford Medicine Children's Health - May 8th, 2024
- Umbilical Cord Blood Transplants: Current Status and Evolving Therapies - May 8th, 2024
- Embattled Cordlife receives letter of demand from client for breach of contract - The Straits Times - May 4th, 2024
- From Cord Blood to Microbiome; The evolution of Rotary's gift to the people of WA - Lifeblood - May 2nd, 2024
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune ... - Nature.com - April 28th, 2024
- Hitting the pavement for cord blood research | Cranbourne Star News - Cranbourne Star News - April 28th, 2024
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
Recent Comments